---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007624"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:40:07.404403+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics raises $24.6M in preferred & debt; 4Q22 revenue $0.1M, net loss $14.9M

## Summary
- Secured $13.6M from Series A preferred stock and $11.1M senior secured convertible note, extending cash runway into 2024.
- 4Q22 EsoGuard test volume 1,174, up 8% sequentially and 288% YoY; projects ~1,600 tests in 1Q23.
- Signed in-network agreement with MultiPlan, expanding access to ~60 million consumers.
- GAAP net loss $14.9M ($0.47/share) in 4Q22; non-GAAP adjusted loss $10.6M ($0.33/share).
- Cash and equivalents $22.5M at Dec 31, 2022, bolstered by subsequent financings.

## SEC filing metadata
- accession: 0001493152-23-007624
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 3.02, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315223007624/0001493152-23-007624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315223007624/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007624
- JSON: https://secwatch.observer/filing/0001493152-23-007624.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.